JAZZ vs LAFAR
Jazz Pharmaceuticals PLC (JAZZ) versus LaFayette Acquisition Corp. Rights (LAFAR) — a side-by-side from cached financials, not a winner call.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
LaFayette Acquisition Corp. Rights (LAFAR) common stock listed on NASDAQ.
Latest reported JAZZ revenue for 2026-06-30 was $2.28B. Net income was $485.9M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
LAFAR does not have a complete income-statement cache yet.
JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1. LAFAR currently screens at market cap $0.
Not investment advice. Open the JAZZ and LAFAR stock pages for the full models.
Not investment advice.